...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biologics: Targets and Therapy >The molecular profile of luminal B breast cancer
【24h】

The molecular profile of luminal B breast cancer

机译：腔B乳腺癌的分子谱

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Molecular profiling studies have found that estrogen receptor-positive (ER+) human breast cancers are comprised of at least two distinct diseases with differing biologies. With the advent of DNA microarrays, global gene expression patterns were used to define the luminal A and luminal B subtypes of ER+ breast cancer, with luminal B cancers showing a more aggressive phenotype including substantially worse outcomes in patients. The luminal B subtype designation could be considered a surrogate for those ER+ tumors having low progesterone receptors, high proliferation, high grade, and predicted poor response to hormone therapy. While they express estrogen receptors, luminal B cancers do not show a corresponding expression of estrogen-regulated genes, and may therefore rely upon alternative pathways for growth. At the molecular level, luminal B cancers appear dramatically distinct from luminal A cancers, at the levels of gene expression, gene copy, somatic mutation, and DNA methylation; luminal B cancers are also genetically and genomically altered to a greater extent than luminal A cancers. While, in the clinical setting, luminal B is typically regarded as an ER+, hormone-sensitive disease, more research is needed into how to better treat it. Comprehensive profiling initiatives, such as The Cancer Genome Atlas, have recently provided us a catalog of mutated or copy altered genes, from which new therapeutic targets could potentially be mined. Candidate pathways that might be targeted in luminal B include those involving growth factor receptors, including HER2 and EGFR, as well as PI3K/Akt/mTor.
机译：分子分析研究发现，雌激素受体阳性（ER +）人乳腺癌由至少两个具有不同生物的疾病组成。随着DNA微阵列的出现，全局基因表达模式用于定义ER +乳腺癌的腔A和腔B亚型，腔B癌症显示出更具侵略性的表型，包括患者的较差的结果。腔B亚型指定可以被认为是那些具有低孕酮受体，高增殖，高等级和预测对激素治疗的不良反应的那些ER +肿瘤的替代品。虽然它们表达雌激素受体，但腔B癌症未显示出相应的雌激素调节基因的表达，因此可能依赖于替代途径进行生长。在分子水平，腔B癌症显着不同于腔A癌，在基因表达，基因拷贝，体细胞突变和DNA甲基化水平。 Luminal B癌症也在遗传上，基因组在更大程度上比腔A癌更大。虽然在临床环境中，腔B通常被认为是ER +，激素敏感性疾病，需要更多的研究如何更好地治疗它。综合分析倡议，例如癌症基因组地图集，最近向我们提供了突变或复制改变基因的目录，从中可以采用新的治疗靶点。可能在腔B中靶向的候选途径包括涉及生长因子受体的途径，包括HER2和EGFR以及PI3K / AKT / MTOR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号